Descending duodenal adenocarcinoma treated with pembrolizumab resulting in complete clinical response: A case report and literature review
Patients with MSI-H DDA exhibiting high PD-L1 expression who are treated with pembrolizumab can achieve sustained CCR.
Authors
- Zi-Hui An (ORCID: https://orcid.org/0009-0007-5805-2320)
- Xiwei Lu (ORCID: https://orcid.org/0000-0003-3620-696X)
- Xianglei Kong (ORCID: https://orcid.org/0000-0002-8736-6018)
- Jiao Liu (ORCID: https://orcid.org/0000-0003-0304-241X)
- Lei Zheng (ORCID: https://orcid.org/0000-0003-4163-2541)
- Liming Gao
- Lanlan Chen
- Siqi Dong (ORCID: https://orcid.org/0000-0001-6928-2761)
- Jun-Li Cao (ORCID: https://orcid.org/0000-0002-6673-458X)
Institutions
- Hebei Medical University (CN)
- First Hospital of Qinhuangdao (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2025-06-13
- DOI
- https://doi.org/10.4251/wjgo.v17.i6.107568
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00